Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-04-02

FDA Approved: PERJETA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for PERJETA (pertuzumab) submitted by Genentech, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Perjeta (pertuzumab)

Snippet

SUPPL AP for PERJETA (PERTUZUMAB)